Immunic (IMUX)
(Delayed Data from NSDQ)
$1.45 USD
+0.06 (4.32%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $1.43 -0.02 (-1.38%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMUX 1.45 +0.06(4.32%)
Will IMUX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IMUX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMUX
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
Immunic (IMUX) Moves to Buy: Rationale Behind the Upgrade
IMUX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails
Other News for IMUX
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec
Immunic Stock (NASDAQ:IMUX): Exploring the Promising Phase 2 CALLIPER Trial
Immunic to present four abstracts at ECTRIMS, says Piper Sandler
Immunic Appoints Jason Tardio as Chief Operating Officer and President
Immunic Stock (IMUX): Deep Dive into Lead Candidate, Vidofludimus Calcium